Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Type

Type

Guidance programme

Advice programme

Showing 31 to 40 of 60

TitleReference numberPublishedLast updated
Pertuzumab for adjuvant treatment of HER2-positive early stage breast cancerTA569
Abemaciclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancerTA563
AlignRT in breast cancer radiotherapyMIB157
Eribulin for treating locally advanced or metastatic breast cancer after 1 chemotherapy regimenTA515
Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancerTA509
Intrabeam radiotherapy system for adjuvant treatment of early breast cancerTA501
Fulvestrant for untreated locally advanced or metastatic oestrogen-receptor positive breast cancerTA503
MammaTyper in vitro diagnostic test for determining breast cancer subtypesMIB135
Palbociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancerTA495
Ribociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancerTA496

Results per page

  1. 10
  2. 25
  3. 50
  4. All